Last $7.81 USD
Change Today -0.05 / -0.64%
Volume 4.9M
NVAX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

novavax inc (NVAX) Snapshot

Open
$7.82
Previous Close
$7.86
Day High
$8.07
Day Low
$7.74
52 Week High
01/30/15 - $8.07
52 Week Low
04/15/14 - $3.34
Market Cap
1.9B
Average Volume 10 Days
9.7M
EPS TTM
$-0.30
Shares Outstanding
238.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVAVAX INC (NVAX)

novavax inc (NVAX) Related Businessweek News

No Related Businessweek News Found

novavax inc (NVAX) Details

Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing recombinant protein nanoparticle vaccines and adjuvants. The company’s vaccine technology platform is based on proprietary recombinant nanoparticle vaccine technology that includes virus-like particles vaccines and protein nanoparticle vaccines. Its vaccine candidates target seasonal influenza, pandemic influenza, and respiratory syncytial virus. The company also develops technology for the production of immune stimulating saponin-based adjuvants. Novavax, Inc. has a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Gaithersburg, Maryland.

213 Employees
Last Reported Date: 03/12/14
Founded in 1987

novavax inc (NVAX) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $448.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $156.3K
Senior Vice President of Corporate Developmen...
Total Annual Compensation: $371.9K
Senior Vice President of Global Manufacturing...
Total Annual Compensation: $284.5K
Compensation as of Fiscal Year 2013.

novavax inc (NVAX) Key Developments

Novavax Names Jill Hoyt as Vice President, Human Resources & Administration

Novavax, Inc. announced that Jill Hoyt has been named Vice President, Human Resources & Administration. Ms. Hoyt joined Novavax in February 2008 as Executive Director, Human Resources & Administration and has been instrumental in the successful growth of the company. Prior to joining Novavax, Ms. Hoyt held management positions of increasing responsibility in a number of companies, including 3e Technologies International, ChoicePoint, and TRW.

Novavax, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 11:30 AM

Novavax, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 11:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.

Novavax, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM

Novavax, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-03-2014 11:00 AM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Stanley C. Erck, Chief Executive Officer, President, Director and Member of Finance Committee.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVAX:US $7.81 USD -0.05

NVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celldex Therapeutics Inc $21.42 USD -0.53
Dynavax Technologies Corp $17.10 USD 0.00
Inovio Pharmaceuticals Inc $8.34 USD -0.16
Progenics Pharmaceuticals Inc $5.98 USD -0.27
ZIOPHARM Oncology Inc $8.95 USD -0.13
View Industry Companies
 

Industry Analysis

NVAX

Industry Average

Valuation NVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 57.3x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 51.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVAVAX INC, please visit www.novavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.